Funding
RTI, LIVER, STEATOHEPATITIS
RTI Health Solutions, an independent nonprofit research organization, received funding under a research contract with Novartis Pharma AG to conduct this study and provide publication support in the form of manuscript writing, styling, and submission. JT, DW, LD, MMB, CAB, and QMA are members of the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium, which is funded by the Innovative Medicines Initiative (IMI2) Program of the European Union under Grant Agreement 777377; this Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. QMA is a Newcastle NIHR Biomedical Research Centre investigator.